NSB 2.08% 4.7¢ neuroscientific biopharmaceuticals ltd

Coming off the back of the company-defining results reported...

  1. 6,941 Posts.
    lightbulb Created with Sketch. 762
    Coming off the back of the company-defining results reported last week in the glaucoma pig model,
    these results also exceeded our expectations and profoundly demonstrate the efficacy of EmtinB in MS
    and across a number of other neurodegenerative conditions”, commented Matthew Liddelow, CEO and
    Managing Director of NeuroScientific Biopharmaceuticals. “These results also indicate positive
    implications for EmtinB treatment of demyelinating conditions that affect the optic nerve, such as optic
    neuritis and the company plans to further explore this as part of our ophthalmology R&D program.”
 
watchlist Created with Sketch. Add NSB (ASX) to my watchlist
(20min delay)
Last
4.7¢
Change
-0.001(2.08%)
Mkt cap ! $6.796M
Open High Low Value Volume
4.8¢ 4.8¢ 4.7¢ $2.173K 45.80K

Buyers (Bids)

No. Vol. Price($)
1 100000 4.5¢
 

Sellers (Offers)

Price($) Vol. No.
4.9¢ 45000 1
View Market Depth
Last trade - 15.56pm 29/03/2024 (20 minute delay) ?
Last
4.8¢
  Change
-0.001 ( 2.13 %)
Open High Low Volume
4.8¢ 4.8¢ 4.8¢ 20988
Last updated 15.28pm 29/03/2024 ?
NSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.